Valuation: QuidelOrtho Corporation

Capitalization 734M 624M 571M 540M 1B 69.22B 1.01B 6.77B 2.64B 33.23B 2.75B 2.7B 115B P/E ratio 2026 *
-8.04x
P/E ratio 2027 * -18.9x
Enterprise value 3.08B 2.62B 2.39B 2.26B 4.2B 290B 4.25B 28.38B 11.06B 139B 11.55B 11.31B 482B EV / Sales 2026 *
1.13x
EV / Sales 2027 * 1.05x
Free-Float
99.18%
Yield 2026 *
-
Yield 2027 * -
1 day+1.67%
1 week-13.77%
Current month-11.38%
1 month-28.85%
3 months-62.75%
6 months-44.75%
Current year-61.83%
1 week 10.21
Extreme 10.21
12.85
1 month 10.21
Extreme 10.21
18
Current year 10.21
Extreme 10.21
35.58
1 year 10.21
Extreme 10.21
38.99
3 years 10.21
Extreme 10.21
90.45
5 years 10.21
Extreme 10.21
180.06
10 years 10.21
Extreme 10.21
306.72
Manager TitleAgeSince
Chief Executive Officer 61 05/05/2024
Director of Finance/CFO 58 -
Chief Operating Officer 57 14/11/2024
Director TitleAgeSince
Chairman 72 10/12/2022
Director/Board Member 71 31/12/2021
Director/Board Member 82 31/12/1992
Change 5d. change 1-year change 3-years change Capi.($)
+1.67%-13.77%-70.10%-87.65% 734M
-2.89%-0.65%-5.57%-40.28% 16.25B
+8.85%+11.10%+73.87%+98.33% 2B
-3.15%+1.53%-21.93%-5.00% 1.16B
+2.11%+1.16%-5.57%-49.18% 756M
+0.65%+6.38%-25.59%-41.34% 732M
-5.11%-3.41%+176.98% - 523M
-16.02%-16.84%+11.62%-56.13% 496M
+0.58%-0.86%-50.43%-61.29% 432M
-1.66%-3.10%-39.26%-34.87% 311M
Average -1.55%+0.37%+4.40%-30.82% 2.34B
Weighted average by Cap. -1.74%+2.10%+0.93%-28.87%

Financials

2026 *2027 *
Net sales 2.71B 2.31B 2.11B 1.99B 3.7B 256B 3.74B 25.03B 9.75B 123B 10.18B 9.97B 425B 2.81B 2.39B 2.19B 2.07B 3.84B 265B 3.88B 25.95B 10.11B 127B 10.56B 10.34B 440B
Net income -205M -174M -159M -151M -279M -19.31B -283M -1.89B -736M -9.27B -769M -753M -32.06B -40M -33.98M -31.12M -29.38M -54.56M -3.77B -55.19M -369M -144M -1.81B -150M -147M -6.26B
Net Debt 2.34B 1.99B 1.82B 1.72B 3.2B 221B 3.23B 21.61B 8.42B 106B 8.79B 8.61B 367B 2.22B 1.88B 1.72B 1.63B 3.02B 209B 3.06B 20.43B 7.96B 100B 8.31B 8.14B 347B
Logo QuidelOrtho Corporation
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Employees
6,500
Date Price Change Volume
08/05/26 10.87 $ +0.93% 362,875
07/05/26 10.77 $ -1.73% 2,792,259
06/05/26 10.96 $ -6.00% 5,473,160
05/05/26 11.66 $ -6.12% 3,186,966
04/05/26 12.42 $ -1.74% 1,783,431
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
10.77USD
Average target price
17.30USD
Spread / Average Target
+60.63%

Quarterly revenue - Rate of surprise